@nanogenomic Andre, your thoughts?https://www.cell.com/cell/fulltext/S0092-8674(20)30620-6?rss=yes#%20 …
-
-
Replying to @AlbertF9999
1) Presence of antibodies doesn't mean the antibodies are effective or will displace ACE2 2) Convalescent serum studies are showing ~15% survival in severe cohorts, right? Why isn't it more? Because ACE2 competes with the antibodies and T-cells and innate immunity having to work.
3 replies 3 retweets 11 likes -
Replying to @nanogenomic
The convalescent serum studies you refer to may be too late in the disease course for an antibody/plasma-based intervention to work. Treated early, we may see much greater efficacy for conv. plasma. But convalescent plasma is anyway not a good dis/proof of concept.
1 reply 0 retweets 1 like -
Replying to @AlbertF9999 @nanogenomic
As for "presence of antibodies doesn't guarantee" But they are demonstrating neutralization activity here, not just confirming that antibodies are present. They are selecting out a whole bunch of them that neutralize. Isn't that a good thing?
2 replies 0 retweets 1 like -
Replying to @AlbertF9999
So yes, while it's great that antibodies are being generated, I fear this will lead to many of the same effects as those seen with the Oxford vaccine. The immunity will be largely T cell driven and high viral loads such as in subways or crowded areas will lead to reinfection.
1 reply 4 retweets 10 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.